Antibody-Drug Conjugate (ADC) Target Proteins Overview
ADC (Antibody-drug conjugate) is an innovative therapeutic strategy that combines the properties of antibodies and drugs, and achieves highly selective targeted therapy for specific target proteins by linking drugs to antibodies. ADC target protein refers to the specific protein target selected in ADC therapy.
The choice of ADC target protein is crucial, it is usually a protein that is overexpressed during the disease process and closely related to the development of the disease. These target proteins can be specific antigens on the surface of tumor cells, such as HER2, CD30, PSMA, etc., or inflammatory mediators overexpressed in inflammatory diseases, such as IL-17, TNF-α, etc.
The working principle of ADC is that the antibody part can effectively deliver the drug to the target cell by specifically binding to the target protein. Once the ADC enters the cell, the drug part will be released to exert its anti-tumor or anti-inflammatory activity, thereby realizing the treatment of the disease.
The selection of ADC target protein is one of the key steps in the development of ADC. Rational target selection can improve the specificity and effectiveness of therapy while reducing adverse effects on normal tissues. By targeting specific target proteins, ADCs have shown potential efficacy in the treatment of cancer, autoimmune diseases, and other diseases, bringing patients more individualized, targeted treatment options.
Research area of ADC Target Proteins
The research field of ADC (Antibody-drug conjugate) target protein widely involves multiple diseases and related proteins. The following are some important areas of research:
1.Cancer Therapy: Research on ADCs in the field of cancer is very active. Researchers are dedicated to discovering and developing ADCs against different cancer-related target proteins. For example, HER2 is an important target protein in breast cancer, and ADC such as Trastuzumab emtansine (T-DM1) is an ADC used to treat HER2-positive breast cancer. In addition, there are studies on ADC target proteins for other cancer types such as prostate cancer, lymphoma, lung cancer, etc.
2.Autoimmune diseases: Autoimmune diseases are diseases in which the immune system attacks its own tissues, such as rheumatoid arthritis and systemic lupus erythematosus. Research on ADC target proteins also involves these diseases. For example, ADCs targeting the IL-6 receptor have shown potential in the treatment of rheumatoid arthritis.
3.Ophthalmic diseases: The research of ADC in the field of ophthalmology is also involved. Macular degeneration is a common eye disease, and the research on ADC target proteins mainly focuses on vascular endothelial growth factor (VEGF) related to macular degeneration.
4.Infectious diseases: The research on ADC target proteins also includes the field of infectious disease treatment. For example, research on ADC target proteins for viral infections such as HIV and influenza virus aims to achieve effective antiviral therapy by targeting virus-related proteins.
This is only a part of the field of ADC target protein research. With the advancement of science and technology, researchers will continue to explore new ADC target proteins and apply them to the treatment of more diseases to provide patients with more effective and individualized treatments. treatment options.
